249 related articles for article (PubMed ID: 26410753)
1. Interest of cyclodextrins in spray-dried microparticles formulation for sustained pulmonary delivery of budesonide.
Dufour G; Bigazzi W; Wong N; Boschini F; de Tullio P; Piel G; Cataldo D; Evrard B
Int J Pharm; 2015 Nov; 495(2):869-78. PubMed ID: 26410753
[TBL] [Abstract][Full Text] [Related]
2. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery.
Nolan LM; Tajber L; McDonald BF; Barham AS; Corrigan OI; Healy AM
Eur J Pharm Sci; 2009 Jul; 37(5):593-602. PubMed ID: 19463948
[TBL] [Abstract][Full Text] [Related]
3. Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy.
Leng D; Kissi EO; Löbmann K; Thanki K; Fattal E; Rades T; Foged C; Yang M
AAPS PharmSciTech; 2019 Mar; 20(3):137. PubMed ID: 30847607
[TBL] [Abstract][Full Text] [Related]
4. Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension.
Shahin HI; Vinjamuri BP; Mahmoud AA; Shamma RN; Mansour SM; Ammar HO; Ghorab MM; Chougule MB; Chablani L
J Control Release; 2019 May; 302():126-139. PubMed ID: 30940497
[TBL] [Abstract][Full Text] [Related]
5. Co-spray dried carbohydrate microparticles: crystallisation delay/inhibition and improved aerosolization characteristics through the incorporation of hydroxypropyl-β-cyclodextrin with amorphous raffinose or trehalose.
Amaro MI; Tajber L; Corrigan OI; Healy AM
Pharm Res; 2015 Jan; 32(1):180-95. PubMed ID: 25074469
[TBL] [Abstract][Full Text] [Related]
6. Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery.
Tewes F; Paluch KJ; Tajber L; Gulati K; Kalantri D; Ehrhardt C; Healy AM
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):604-13. PubMed ID: 23563102
[TBL] [Abstract][Full Text] [Related]
7. Design and characterization of emulsified spray dried alginate microparticles as a carrier for the dually acting drug roflumilast.
Mahmoud AA; Elkasabgy NA; Abdelkhalek AA
Eur J Pharm Sci; 2018 Sep; 122():64-76. PubMed ID: 29928985
[TBL] [Abstract][Full Text] [Related]
8. Budesonide dry powder for inhalation: effects of leucine and mannitol on the efficiency of delivery.
Rattanupatam T; Srichana T
Drug Deliv; 2014 Sep; 21(6):397-405. PubMed ID: 24401124
[TBL] [Abstract][Full Text] [Related]
9. Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery.
Pozzoli M; Traini D; Young PM; Sukkar MB; Sonvico F
Drug Dev Ind Pharm; 2017 Sep; 43(9):1510-1518. PubMed ID: 28425305
[TBL] [Abstract][Full Text] [Related]
10. Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study.
Naikwade SR; Bajaj AN; Gurav P; Gatne MM; Singh Soni P
AAPS PharmSciTech; 2009; 10(3):993-1012. PubMed ID: 19649711
[TBL] [Abstract][Full Text] [Related]
11. Application of cyclodextrins in antibody microparticles: potentials for antibody protection in spray drying.
Ramezani V; Vatanara A; Seyedabadi M; Nabi Meibodi M; Fanaei H
Drug Dev Ind Pharm; 2017 Jul; 43(7):1103-1111. PubMed ID: 28276783
[TBL] [Abstract][Full Text] [Related]
12. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
13. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model.
Oh YJ; Lee J; Seo JY; Rhim T; Kim SH; Yoon HJ; Lee KY
J Control Release; 2011 Feb; 150(1):56-62. PubMed ID: 21070826
[TBL] [Abstract][Full Text] [Related]
14. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs.
Ungaro F; d'Emmanuele di Villa Bianca R; Giovino C; Miro A; Sorrentino R; Quaglia F; La Rotonda MI
J Control Release; 2009 Apr; 135(1):25-34. PubMed ID: 19154761
[TBL] [Abstract][Full Text] [Related]
15. Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations.
Sahib MN; Darwis Y; Peh KK; Abdulameer SA; Tan YT
Int J Nanomedicine; 2011; 6():2351-66. PubMed ID: 22072872
[TBL] [Abstract][Full Text] [Related]
16. [Preparation of budesonide sustained-release dry powder for inhalation and influence of lactose content].
Liang ZL; Wang XH; Ni R; Zhang L; Muenster U; Mao SR
Yao Xue Xue Bao; 2015 Sep; 50(9):1180-5. PubMed ID: 26757557
[TBL] [Abstract][Full Text] [Related]
17. Inhalation powder development without carrier: How to engineer ultra-flying microparticles?
Lechanteur A; Gresse E; Orozco L; Plougonven E; Léonard A; Vandewalle N; Lumay G; Evrard B
Eur J Pharm Biopharm; 2023 Oct; 191():26-35. PubMed ID: 37595762
[TBL] [Abstract][Full Text] [Related]
18. Co-spray dried resveratrol and budesonide inhalation formulation for reducing inflammation and oxidative stress in rat alveolar macrophages.
Trotta V; Lee WH; Loo CY; Young PM; Traini D; Scalia S
Eur J Pharm Sci; 2016 Apr; 86():20-8. PubMed ID: 26944422
[TBL] [Abstract][Full Text] [Related]
19. Poly(malic acid)-budesonide nanoconjugates embedded in microparticles for lung administration.
Tessier B; Moine L; Peramo A; Tsapis N; Fattal E
Drug Deliv Transl Res; 2024 Aug; 14(8):2062-2078. PubMed ID: 38517568
[TBL] [Abstract][Full Text] [Related]
20. Budesonide/cyclodextrin complex-loaded lyophilized microparticles for intranasal application.
Kim JE; Cho HJ; Kim DD
Drug Dev Ind Pharm; 2014 Jun; 40(6):743-8. PubMed ID: 23547762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
